key: cord-0078548-b6sgy9ql
authors: Jain, Ankur
title: Comments on COVID-19 and AL Amyloidosis, the Missing Links
date: 2022-05-24
journal: Am J Med
DOI: 10.1016/j.amjmed.2022.02.011
sha: 0de6389fae8edbaeaf456660bbac6eb27d8c049b
doc_id: 78548
cord_uid: b6sgy9ql

nan

To the Editor:

Crees and Stockerl-Goldstein 1 recently reviewed the management of light chain (AL) amyloidosis during the coronavirus disease 2019 (COVID-19) pandemic. While the literature discussed by authors is pertinent, certain lacunae in the diagnosis, prevention, and management need attention.

Monoclonal protein in AL amyloidosis could be secreted by either plasma cells or, rarely, B-cells. 2 In addition to direct organ toxicity due to tissue deposition, monoclonal protein could cause 1) immunoparesis leading to increased risk and severity of infections, and an impaired vaccination response; and 2) coagulation disturbance leading to bleeding, thrombosis, or reduced antithrombin levels. 3 COVID-19 has been associated with a potent thrombo-inflammatory milieu that causes thromboembolic complications. 3 An overlapping multiorgan involvement in AL amyloidosis and COVID-19 has several implications with respect to the drug administration. 3 In light of these observations and the current evidence, additional points are addressed below:

1. Diagnostic challenges for AL amyloidosis during COVID-19.

2. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) booster vaccination in patients with AL amyloidosis. 3. Management of indolent B-cell non-Hodgkin lymphoma-associated AL amyloidosis during the COVID-19 pandemic. 4. Management and response assessment in patients with AL amyloidosis infected with COVID-19. 5. Toxicity consideration of anti-COVID drugs in patients with AL amyloidosis. 6. Therapeutic implications of coagulation derangement of the 2 disorders.

These points are discussed in the Table 3 -6 under 3 heads: 1) management of AL amyloidosis during COVID-19 pandemic; 2) management of AL amyloidosis in patients with COVID-19; and 3) management of COVID-19 in patients with AL amyloidosis. Repeat SARS-CoV-2 vaccination at least 6-months after the last Rituximab dose Booster vaccination (mRNA vaccines) could augment antibody response following the second dose in patients with hematological malignancies 4 

COVID-19 and light chain amyloidosis, adding insult to injury

Pathophysiology and management of monoclonal gammopathy of renal significance

Potential 'significance' of monoclonal gammopathy of 'undetermined significance' during COVID-19 pandemic

BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses

Baricitinib plus remdesivir for hospitalized adults with Covid-19

Molnupiravir for oral treatment of Covid-19 in non-hospitalized patients

Consider booster vaccination for patients with AL amyloidosis who have completed the 2-dose schedule.Nephrological considerations 3 Maintain COVID appropriate behaviour in the dialysis units 1 The American Journal of Medicine, Vol 135, No 6, June 2022